miR-342-3p exerts its potential anti-cancer effect by inhibiting the expression of DNA-binding inhibitor 4 (ID4), which downregulates the resistance of breast cancer cells to doxorubicin, fluorouracil, and cisplatin [131]. This evidence concerns the gene ID4 and breast carcinoma.